Accumulating evidence demonstrating YAP and TAZ as oncogenic effectors and essential cancer dependencies in HNSCC supports the development of novel oncotherapeutics against YAP/TAZ [17,18]. This evidence concerns the gene YAP1 and head and neck squamous cell carcinoma.